[{"orgOrder":0,"company":"Codexis","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Agreement","leadProduct":"Sitagliptin Phosphate","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Codexis","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Codexis \/ Merck","highestDevelopmentStatusID":"12","companyTruncated":"Codexis \/ Merck"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Sitagliptin Phosphate","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Lifesciences \/ Not Applicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Sitagliptin Phosphate","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Sun Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co \/ Sun Pharmaceutical"},{"orgOrder":0,"company":"George Medicines","sponsor":"CUREator","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2022","type":"Financing","leadProduct":"Metformin","moa":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"George Medicines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"George Medicines \/ CUREator","highestDevelopmentStatusID":"8","companyTruncated":"George Medicines \/ CUREator"},{"orgOrder":0,"company":"Prague Scientific","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CZECH REPUBLIC","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Sitagliptin Phosphate","moa":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Prague Scientific","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Prague Scientific \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Prague Scientific \/ Not Applicable"},{"orgOrder":0,"company":"Akums Drugs & Pharmaceuticals Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Sitagliptin Phosphate","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Akums Drugs & Pharmaceuticals Ltd","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Akums Drugs & Pharmaceuticals Ltd \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Akums Drugs & Pharmaceuticals Ltd \/ Not Applicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Sitagliptin Phosphate","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Lifesciences \/ Not Applicable"},{"orgOrder":0,"company":"NeuroBo Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"DA-1241","moa":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"NeuroBo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"","sponsorNew":"NeuroBo Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroBo Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Undisclosed","sponsor":"Cosmos Health","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2023","type":"Acquisition","leadProduct":"Sitagliptin Phosphate","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Undisclosed","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Undisclosed \/ Cosmos Health","highestDevelopmentStatusID":"12","companyTruncated":"Undisclosed \/ Cosmos Health"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Sitagliptin Phosphate","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Lupin Ltd \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lupin Ltd \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals for MK 0431 phosphate

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
filter

Year

filter

DEALS // DEV.

filter

Country

filter
Sponsor
filter

Therapeutic Area

filter

Study Phase

filter

Deal Type

filter

Product Type

filter

Dosage Form

filter

Lead Product

filter

Target

Therapeutic Area by Lead Product

ForexGraph

Study Phase by Lead Product

ForexGraph

Company by Lead Product

ForexGraph

Top Deals by Deal Size (USD bn)

ForexGraph

01

Biotech Showcase
Not Confirmed
Biotech Showcase
Not Confirmed

Details : Janumet-Generic (sitagliptin & metformin HCl) is a DPP-4 inhibitor & biguanide FDC product indicated as adjunct to diet & exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Brand Name : Janumet-Generic

Molecule Type : Small molecule

Upfront Cash : Not Applicable

November 28, 2024

Lead Product(s) : Sitagliptin Phosphate,Metformin

Therapeutic Area : Endocrinology

Highest Development Status : Approved

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

02

Biotech Showcase
Not Confirmed
Biotech Showcase
Not Confirmed

Details : DA-1241, a GPR119 agonist, is in Phase 2 trials with sitagliptin, a DPP4 inhibitor, for steatohepatitis treatment.

Brand Name : DA-1241

Molecule Type : Small molecule

Upfront Cash : Not Applicable

January 18, 2024

Lead Product(s) : DA-1241,Sitagliptin Phosphate

Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

Highest Development Status : Phase II

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

03

Undisclosed

Country arrow
Biotech Showcase
Not Confirmed

Undisclosed

Country arrow
Biotech Showcase
Not Confirmed

Details : Through the acquisition, Cosmos will gain the license and rights for DIABIT-IS X, a drug that contains the active substance sitagliptin and is used in the treatment of type-2 diabetes.

Brand Name : DIABIT-IS X

Molecule Type : Small molecule

Upfront Cash : Undisclosed

December 20, 2023

Lead Product(s) : Sitagliptin Phosphate

Therapeutic Area : Endocrinology

Highest Development Status : Approved

Sponsor : Cosmos Health

Deal Size : Undisclosed

Deal Type : Acquisition

blank

04

Biotech Showcase
Not Confirmed
Biotech Showcase
Not Confirmed

Details : Zituvio (Sitagliptin) tablets A is a dipeptidyl peptidase-4 (DPP-4) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Brand Name : Zituvio

Molecule Type : Small molecule

Upfront Cash : Not Applicable

October 20, 2023

Lead Product(s) : Sitagliptin Phosphate

Therapeutic Area : Endocrinology

Highest Development Status : Approved

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

05

Biotech Showcase
Not Confirmed
Biotech Showcase
Not Confirmed

Details : Sitagliptin, Pioglitazone & Metformin are combined for the treatment of diabetes. Metformin, coupled with the functional and corrective influence of pioglitazone on beta-cell and metabolic syndrome and the stability of Sitagliptin, make an effective solu...

Brand Name : Undisclosed

Molecule Type : Small molecule

Upfront Cash : Not Applicable

July 27, 2023

Lead Product(s) : Sitagliptin Phosphate,Pioglitazone,Metformin

Therapeutic Area : Endocrinology

Highest Development Status : Approved

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

06

Biotech Showcase
Not Confirmed
Biotech Showcase
Not Confirmed

Details : GMRx4 is being developed to provide a synergistic effect from three best-in-class type 2 diabetes treatments – metformin, dapagliflozin and sitagliptin – and, in an ultra-low-dose, single pill formulation, aims to be a more effective, simpler and saf...

Brand Name : GMRx4

Molecule Type : Small molecule

Upfront Cash : Undisclosed

July 20, 2022

Lead Product(s) : Metformin,Dapagliflozin,Sitagliptin Phosphate

Therapeutic Area : Endocrinology

Highest Development Status : Phase II

Sponsor : CUREator

Deal Size : $1.0 million

Deal Type : Financing

blank

07

Biotech Showcase
Not Confirmed
Biotech Showcase
Not Confirmed

Details : Januvia (sitagliptin), a class of dipeptidyl peptidase (DPP4) inhibitors, is used with a proper diet and exercise program and possibly with other medications to control high blood sugar.

Brand Name : Januvia

Molecule Type : Small molecule

Upfront Cash : Not Applicable

July 07, 2022

Lead Product(s) : Sitagliptin Phosphate

Therapeutic Area : Endocrinology

Highest Development Status : Approved

Sponsor : Sun Pharmaceutical Industries Limited

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

08

Biotech Showcase
Not Confirmed
Biotech Showcase
Not Confirmed

Details : Sitagliptin is a DPP-4 inhibitor, which is believed to exert its actions in patients with type 2 diabetes by slowing the inactivation of incretin hormones.

Brand Name : Sitagliptin-Generic

Molecule Type : Small molecule

Upfront Cash : Not Applicable

October 12, 2021

Lead Product(s) : Sitagliptin Phosphate

Therapeutic Area : Endocrinology

Highest Development Status : Phase III

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

09

Biotech Showcase
Not Confirmed
Biotech Showcase
Not Confirmed

Details : Under a research and development agreement, Codexis and Merck leveraged Codexis’ CodeEvolver® enzyme engineering platform technology to design a novel, proprietary enzyme to serve as a biocatalyst in the sitagliptin manufacturing process.

Brand Name : Januvia

Molecule Type : Small molecule

Upfront Cash : Undisclosed

September 09, 2021

Lead Product(s) : Sitagliptin Phosphate

Therapeutic Area : Endocrinology

Highest Development Status : Approved

Sponsor : Merck & Co

Deal Size : Undisclosed

Deal Type : Agreement

blank

10

Biotech Showcase
Not Confirmed
Biotech Showcase
Not Confirmed

Details : Zydus’ Sitagliptin base contains the active moiety sitagliptin in a different form than used in the branded reference product, Januvia (sitagliptin phosphate).

Brand Name : Januvia

Molecule Type : Small molecule

Upfront Cash : Not Applicable

September 06, 2021

Lead Product(s) : Sitagliptin Phosphate

Therapeutic Area : Endocrinology

Highest Development Status : Approved

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank